Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) FCF Margin (2019 - 2025)

Historic FCF Margin for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to 987.37%.

  • Kymera Therapeutics' FCF Margin rose 3491900.0% to 987.37% in Q3 2025 from the same period last year, while for Sep 2025 it was 96725.63%, marking a year-over-year increase of 968948800.0%. This contributed to the annual value of 6688.35% for FY2024, which is 65136500.0% down from last year.
  • Latest data reveals that Kymera Therapeutics reported FCF Margin of 987.37% as of Q3 2025, which was up 3491900.0% from 527.88% recorded in Q2 2025.
  • In the past 5 years, Kymera Therapeutics' FCF Margin registered a high of 171.47% during Q4 2024, and its lowest value of 1336.57% during Q3 2024.
  • Over the past 5 years, Kymera Therapeutics' median FCF Margin value was 344.97% (recorded in 2022), while the average stood at 391.28%.
  • Per our database at Business Quant, Kymera Therapeutics' FCF Margin plummeted by -10741400bps in 2021 and then soared by 3491900bps in 2025.
  • Over the past 5 years, Kymera Therapeutics' FCF Margin (Quarter) stood at 254.36% in 2021, then grew by 3bps to 247.28% in 2022, then skyrocketed by 97bps to 7.48% in 2023, then soared by 2394bps to 171.47% in 2024, then crashed by -676bps to 987.37% in 2025.
  • Its FCF Margin was 987.37% in Q3 2025, compared to 527.88% in Q2 2025 and 360.26% in Q1 2025.